Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca, Oxford Report High Effectiveness

Based on data from their US clinical trial, AstraZeneca and the University of Oxford say their SARS-CoV-2 vaccine is highly effective, the New York Times reports.

Nearly 34,500 individuals took part in the trial, which showed the vaccine was 79 percent effective in protecting against symptomatic COVID-19, according to AstraZeneca. The company adds in its press release that the vaccine exhibited 100 percent efficacy at preventing severe disease and hospitalizations. The vaccine is given as two doses four weeks apart.

Regulators, mostly in Europe, briefly paused the use of the AstraZeneca-University of Oxford vaccine for a review of concerns that it led to blood clots in some individuals, the Times notes. NPR adds that the European Medicines Agency announced Thursday that the vaccine is safe and effective and that its benefits outweigh any potential risks, prompting many countries to resume its use. An analysis of results from the US trial results also found no increased risk of thrombosis, according to AstraZeneca.

The company further says it plans to seek an Emergency Use Authorization from the US Food and Drug Administration.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.